Remove Allergies Remove Containment Remove Dermatology Remove Licensing
article thumbnail

17 creams to STOP ITCHING FAST

Druggist

Lotions: contain the least amount of oils and higher amounts of water with non-greasy consistency. Clobetasone has a narrow licensed use. It contains a combination of miconazole (an antifungal drug) and hydrocortisone 1% (steroid). Creams: optimal amount of oil vs water, but in higher oil amounts than lotions. Chickenpox.

article thumbnail

Tiziana announces appointment of Dr Neil Graham MBBS, MD, MPH as Chief Medical Officer

The Pharma Data

Virology, Respiratory, Dermatology, Allergy, & Rheumatology) in early & late stage Clinical Development and in Medical Affairs, with a strong track record for Developing and Accelerating Phase I–IV programs. THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Bayer: successful start to 2021

The Pharma Data

This business developed positively in the Europe/Middle East/Africa region and in Latin America, partly as a result of higher prices, whereas it shrank in North America, in part due to a license expiration. The performance remained ahead of competition with growth momentum in the Dermatology and Nutritionals categories, with business up by 6.6

Sales 40
article thumbnail

Clinical Catch-Up: January 18-22 | BioSpace

The Pharma Data

It inked a deal with the National Institute of Allergy and Infectious Diseases (NIAID) to launch a Phase I trial. National Institute of Allergy and Infectious Diseases (NIAID), of bamlanivimab (LY-CoV555) decreased the risk of COVID-19 among residents and staff of long-term care facilities, i.e., nursing homes.

Trials 52
article thumbnail

Top 30 Pharma and Biotech Companies in 2023: Statistics and Trends

XTalks

It contains the antiviral medications nirmatrelvir and ritonavir. Late in 2022, AbbVie partnered with HotSpot Therapeutics and announced an exclusive worldwide collaboration and option to license agreement for their interferon regulatory factor 5 (IRF5) inhibitor program for autoimmune disease treatment. billion in 2022.

Sales 98